nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.051	0.051	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0508	0.0508	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0435	0.0435	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0433	0.0433	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0422	0.0422	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0421	0.0421	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0393	0.0393	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0392	0.0392	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0365	0.0365	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0364	0.0364	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0355	0.0355	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0354	0.0354	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.033	0.033	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0329	0.0329	CbGpPWpGaD
Cevimeline—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0275	0.0275	CbGpPWpGaD
Cevimeline—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0274	0.0274	CbGpPWpGaD
Cevimeline—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0231	0.0231	CbGpPWpGaD
Cevimeline—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0231	0.0231	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—HDC—Gilles de la Tourette syndrome	0.021	0.021	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0192	0.0192	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0187	0.0187	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.0122	0.0122	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.0102	0.0102	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00994	0.00994	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00926	0.00926	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00839	0.00839	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00836	0.00836	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00814	0.00814	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00812	0.00812	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00759	0.00759	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00756	0.00756	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00719	0.00719	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00716	0.00716	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00698	0.00698	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00696	0.00696	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00687	0.00687	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00685	0.00685	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0065	0.0065	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00648	0.00648	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00615	0.00615	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00613	0.00613	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00547	0.00547	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00546	0.00546	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00531	0.00531	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00531	0.00531	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0053	0.0053	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0053	0.0053	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00523	0.00523	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00495	0.00495	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00493	0.00493	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00455	0.00455	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00454	0.00454	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00347	0.00347	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00346	0.00346	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00313	0.00313	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00309	0.00309	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00308	0.00308	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.003	0.003	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00299	0.00299	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00281	0.00281	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0028	0.0028	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0028	0.0028	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00279	0.00279	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00273	0.00273	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00272	0.00272	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00254	0.00254	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00253	0.00253	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.00205	0.00205	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00196	0.00196	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00195	0.00195	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00178	0.00178	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00177	0.00177	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00166	0.00166	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00165	0.00165	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00161	0.00161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00161	0.00161	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.0015	0.0015	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.0015	0.0015	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00105	0.00105	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00105	0.00105	CbGpPWpGaD
